

Frontal infrared thermography in healthy individuals and chronic migraine patients: reliability of the method

Journal:	<i>Cephalalgia</i>
Manuscript ID	CHA-00474-OA-2017.R2
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Antonaci, Fabio; Universita degli Studi di Pavia, Brain and behavioural sciences; Fondazione Istituto Neurologico Nazionale C Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Headache center Rossi, Elena; Politecnico di Milano, Dipartimento di Elettronica, Informazione e Bioingegneria Voiticsovich-Iosob, Cristina; State Medical and Pharmaceutical University "Nicolae Testemitanu", Medicine Dalla Volta, Giorgio; Istituto Clinico Citta Di Brescia, UO Neurologia Marceglia, Sara; Universita degli Studi di Trieste Dipartimento di Ingegneria e Architettura, Dipartimento di Ingegneria e Architettura; Ospedale Maggiore Policlinico, UO Neurofisiopatologia
Key Words:	Frontal thermography, chronic migraine, cold patch, standard procedure, reliability

SCHOLARONE™
Manuscripts

1
2
3 1 **Frontal infrared thermography in healthy individuals and chronic**
4
5
6 2 **migraine patients: reliability of the method**
7
8
9 3

10 4 Fabio Antonaci, MD, PhD¹, Elena Rossi, PhD^{2,3}, Cristina Voiticovschi-Iosob, MD⁴, Giorgio
11
12
13 5 Dalla Volta, MD⁵, and Sara Marceglia, PhD^{6*}
14
15 6

17 7 *¹Headache Centre, C. Mondino National Institute of Neurology Foundation, IRCCS,*

18
19 8 *Department of Brain and Behavioral Sciences University of Pavia, Italy.*

20
21 9 *²Dipartimento di Elettronica, Informazione e Bioingegneria. Politecnico di Milano. Milan,*
22
23 10 *Italy.*

24
25
26 11 *³Newronika srl, Milan, Italy*

27
28 12 *⁴State Medical and Pharmaceutical University “Nicolae Testemitanu”, Chisinau, Moldova.*

29
30 13 *⁵U.O Neurologia, Istituto Clinico Città di Brescia, Brescia, Italy.*

31
32 14 *⁶Dipartimento di Ingegneria e Architettura. Università degli Studi di Trieste. Trieste, Italy.*
33
34 15

35
36 16 * Corresponding author

37 17 Dipartimento di Ingegneria e Architettura, Università degli Studi di Trieste, via A. Valerio 10,

38 18 34127 Trieste, ITALIA

39 19 tel: +39 040 558 3450

40 20 email: smarceglia@units.it
41
42
43 21

44
45 22 **Keywords**

46
47 23 Frontal Thermography (FIT); Chronic Migraine; Cold Patch; Standard Procedure; Reliability
48
49 24
50
51 25
52
53 26
54
55 27
56
57
58
59
60

1
2
3 **1 Abbreviations**

4
5 2 AI – Asymmetry Index

6
7 3 ANOVA – analysis of variance

8
9 4 BMS - between-subjects mean square

10
11 5 CV - Coefficient of Variation

12
13 6 EMS - residual mean square

14
15 7 FIT – Frontal Infrared Thermography

16
17 8 ICC - intra-class correlation coefficient

18
19 9 JMS - within-subjects mean square

20
21
22 10 tDCS - transcranial direct current stimulation

23
24 11 VAS - Visual Analogue Scale

25
26 12

27
28 13

29
30
31 14

1
2
3 1 **Abstract**

4
5 2 **Background:** The use of Frontal infrared thermography in the diagnosis of primary
6
7 3 headaches provided scattering results due to measurement fluctuations and different types of
8
9 4 headaches or research protocols.

10
11 5 **Objective:** This study aims to assess the reliability of Frontal infrared thermography in
12
13 6 healthy individuals and provide a preliminary evaluation in chronic migraine patients using a
14
15 7 commercial infrared thermal camera.

16
17
18 8 **Methods:** Thermographic images were acquired in 20 controls and 15 patients at 3
19
20 9 consecutive time-points in two daily sessions. The Side Difference and Asymmetry Index
21
22 10 parameters were defined. The reproducibility of the measurements, the correlation of
23
24 11 Asymmetry Index and Side Difference with clinical evaluations and patient perceptions, and
25
26 12 the ability of the parameters to discriminate between patients and controls were investigated.

27
28
29 13 **Results:** We reported a good reproducibility of the measurements (Inter-class Correlation
30
31 14 Coefficient >0.75 and Coefficient of Variation $<13.4\%$), independent from external factors.
32
33 15 The Side Difference was significantly different between patients and controls ($p<0.001$). The
34
35 16 Asymmetry Index showed good correlation with the side of unilateral pain ($p=0.0056$).

36
37 17 **Conclusions:** Frontal infrared thermography can be used to quantify the difference between
38
39 18 the right and the left side of frontal vascular changes in chronic migraine patients, provided
40
41 19 that standardized conditions are satisfied.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

2 Infrared Thermography detects infrared light emitted by the human body to visualize changes
3 in heat due to abnormalities in the skin surface blood flow of diseased areas. This non-
4 invasive and non-radiative imaging technique has different clinical applications including the
5 detection of circulatory and/or inflammatory disorders such as rheumatoid arthritis,
6 Raynaud's disease or osteoarthritis of the knee¹. It was also demonstrated that thermography
7 is able to capture thermal gradient in facial areas characterizing healthy individuals².

8 However, the literature investigating the use of external carotid region (forehead) thermal
9 imaging for the characterization of vascular headaches did not reach consistent results due to
10 different types of headache evaluated, different timing of patients' evaluation (during
11 headache attack or in headache free interval), different technologies used for image
12 acquisition, and different methods for imaging or statistical analysis.

13 In 1986, Swerdlow and Dieter³ comparing electronic thermography between 275 headache
14 patients and 45 controls, defined the "Cold Patch" as a region of the face where the
15 temperature is cooler (less than 0.5°C) than the surrounding areas^{3,4}. The presence of the cold
16 patch is more frequent in vascular headaches than in healthy subjects or patients with tension
17 type headache, psychogenic headaches or post-traumatic headaches.

18 There is an open question on whether the cold patch is a "fixed" entity⁵ or whether it
19 decreases with therapy^{6,7}. In fact, whereas according to Swerdlow and Dieter, "the vascular
20 cold patch is independent of prognosis and is most likely a permanent element of a vascular
21 headache sufferer's facial thermal pattern"⁵, in 1991, Dalla Volta et al.⁷ suggested that the
22 "cold patch" in vascular headache patients is ipsilateral to the prevailing side of pain and that
23 the cooler area decreased after 6 months of prophylactic therapy. The differences observed by
24 the two groups may be explained in terms of experimental protocol and patient's selection
25 that introduced a higher variability in the cold patch response⁷.

1
2
3 1 Anyway, there is large consensus on the fact that the cold patch represents an asymmetry in
4
5 2 the forehead of migraine patients. Unfortunately, the location of the cold patch is seldom
6
7 3 related to the side of the pain⁵ probably due to the variation of temperature during headache
8
9 4 attack or due to the lateralization of the headache (unilateral or bilateral) as measured by
10
11 5 Drummond and Lance^{8,9}.

12
13 6 Finally, FIT, in conjunction with nitroglycerine administration, was suggested as a novel non-
14
15 7 invasive approach to study vascular processes underlying headaches¹⁰.

16
17
18 8 Taken together, all these studies demonstrate that FIT can be used as diagnostic tool in
19
20 9 migraine with and without aura, in cluster headache and in other headache types.

21
22 10 In the light of previous observations and of new possible therapeutic applications, the present
23
24 11 study has two primary end points: (1) to evaluate the reliability of FIT measurements in
25
26 12 controls and chronic migraine patients using modern commercial infrared thermal camera; (2)
27
28 13 to verify whether FIT-based parameters correlate both with the visual evaluation of FIT by an
29
30 14 expert clinician and with patient's perception of pain side (at least in case of unilateral pain).

31
32
33 15

34 35 16 **Materials and methods**

36 37 17 *Subjects*

38
39 18 Thirty five right handed volunteers (26 females and 9 males) with a mean age of 35±11.6
40
41 19 years (range: 20-55) were enrolled at the Headache centre of the Fondazione IRCCS Istituto
42
43 20 Neurologico Nazionale Casimiro Mondino. All the subjects were not medicated at the time of
44
45 21 testing.

46
47
48 22 15 of the 35 volunteers (3 males) suffered from chronic migraine with medication overuse, as
49
50 23 assessed according to the IHS Classification¹¹. They were examined while hospitalized and
51
52 24 during a washout period from analgesics or other symptomatic treatment, including non-
53
54 25 headache medication. Patients were not on dietary/smoking restrictions ahead of

1 measurements. Patients did not use preventive treatment and underwent daily parenteral
2 detoxification (saline, cyanocobalamin, folic acid, nicotinamide, glutathione, delorazepam
3 and metoclopramide on demand). Patients were assessed on the second or third day after
4 symptomatic medication withdrawal that started on the day of hospital admission. No
5 symptomatic medication was allowed during the evaluation period but local ice bag (at least
6 one day apart from the examination). Hence, patients were generally with headache during the
7 examination. Pain severity was evaluated before each examination on a 0-3-score Visual
8 Analogue Scale (0: no pain, 1: mild pain, 2: moderate pain 3: severe pain) with a mean value
9 of [mean±SE] 1.88 ± 0.078 .

10 The remaining 20 of the 35 volunteers were used as controls since they suffered from
11 migraine or tension type headache no more than 1-2 times a year.

12 The study was approved by the institutional review board (Ethical Committee of the
13 Fondazione IRCCS Istituto Neurologico Nazionale Casimiro Mondino, date of approval: July
14 29th 2013) and conformed with the Declaration of Helsinki. All patients signed written
15 informed consent before participating to the study.

16 ***Frontal Infrared Thermography***

17 FIT was assessed with a modern infrared thermal camera (model LT3, produced by Zhejiang
18 Dali Technology Co. Ltd) characterized by a thermal sensitivity below 0.08°C at 30°C ,
19 according to suggested guidelines^{12,13}. FIT measured the spatial distribution of the heat over
20 the human face (object emissivity 0.98): the camera was placed at distance of 1 meter from
21 the subject in a room with stable temperature ($23.6 \pm 1.57^{\circ}\text{C}$). To ensure comparability
22 between patients and controls, since controls do not have a “cold area”, the temperature was
23 evaluated in two target points (left and right side) in the frontal polar sites. In patients, we
24 identified the coolest point in the side showing the cold patch, and then we identified its
25 symmetric on the other side of the head (equidistant from the nasion, Fig.1). In controls there

1 is no cold patch, so we used two symmetric points equidistant from the nasion on a radius of
2 2cm (Fig.2). This protocol allowed repeatability and comparability among subjects.

3 ***Study design***

4 All measurements were taken in two test sessions (T1 and T2) for all subjects. The second
5 session (T2) was run at least one day apart in order to evaluate the intra-subject variations in
6 FIT. During each session (T1 and T2), the measurements were repeated three times (m1, m2,
7 m3) by the same experimenter after 10 minutes of rest between each measurement. Room
8 temperature was recorded during each session. Images were taken approximately at the same
9 time of the day in each patient (10-12 a.m. or 2.00-4.00 p.m.).

11 ***Data analysis***

12 *Reliability of Frontal Thermography (FIT)*

13 In order to verify whether measurements were influenced by external factors, correlation
14 analysis was computed with respect to room temperature, sex and age of subjects, both at T1
15 and at T2, using m1, m2, and m3 as dependent variables.

16 Student's paired t-Test was used to determine whether three measurements belonging to the
17 same session (m1 vs m2, m2 vs m3, m1 vs m3) had the same mean. The Bonferroni
18 correction for repeated measures was applied ($p < 0.016$).

19 Reliability of measurements was investigated using the intra-class correlation coefficient
20 (ICC), defined as the fraction of variance that is caused by the variation between subjects.

21 Thus, if the variance between tests is smaller than the variance between subjects then ICC is
22 close to 1. According to Fleiss, ICC values above 0.75 generally mean "excellent"
23 reliability¹⁴. The intra-class correlation coefficient (ICC) was calculated for FIT at each point:
24 data during a single session (T1 and T2) were analysed using a Two Factor ANOVA without

1 Replication (factors: subjects and FIT readings m_i) and the value from the analysis of variance
 2 table were substituted into equation (1):

$$3 \quad ICC_{2,1} = (BMS - EMS) / (BMS + EMS + 2(JMS - EMS) / n) \quad (1)$$

4 where BMS is the between-subjects mean square, EMS is the residual mean square, JMS is
 5 the within-subjects mean square, n is number of subjects¹⁵.

6 The reproducibility of the method was tested by calculating the Coefficient of Variation (CV)
 7 during the first test session^{16,17}. For each comparison between measurements (m_1 vs m_2 , m_2
 8 vs m_3 , m_1 vs m_3) the coefficient of variation (equation 2) was calculated as the absolute
 9 value of:

$$10 \quad CV = 100 * | (m_i - m_{i+1}) / ((m_i + m_{i+1}) / 2) | \quad (2)$$

11 where m_i is the first reading (test) and m_{i+1} is the second one (retest). The numerator is the
 12 difference between two consecutive measurements and the denominator is the average of the
 13 two measurements. In this way, the Coefficient of Variation is the percentage difference
 14 between two readings. For each subject the coefficient of variation was computed for the three
 15 intra-session comparisons and then averaged across subjects.

16 In order to evaluate the intra-subject variations in FIT, a two-way analysis of variance with
 17 replication (2-way ANOVA) was performed for a statistical comparison between two
 18 different test sessions (T1 and T2).

19 *Characterization of images comparing controls and patients*

20 In order to verify the difference between migraine FIT measurement and healthy subject FIT
 21 measurements, we defined two parameters:

- 22 ▪ the Asymmetry Index [14] (equation 3)

$$23 \quad AI = 2 * ((T_{left} - T_{right}) / (T_{left} + T_{right})) \quad (3)$$

24 Where T_{left} is the temperature on the left forehead and T_{right} is the temperature of the right
 25 forehead. AI was calculated in order to assess the lateralization of FIT. If the temperature

1 measurement on the two sides is the same, then the asymmetry index is equal to 0. Positive AI
2 value means that the cold patch is located on the right side of the forehead. Conversely, a
3 negative asymmetry index means a lateralization on the left side.

4 ▪ the absolute value of percentage difference between left and right side

$$5 \text{ Side Difference (\%)} = 100 * | 2 * (T_{\text{left}} - T_{\text{right}} / T_{\text{left}} + T_{\text{right}}) | \quad (4)$$

6 SideDifference (equation 4) is the difference between left and right side as a percentage of the
7 average temperature in forehead.

8 Both parameters were calculated from all the measurements of each patients (15*6=90
9 observations) and controls (20*6=120 observations). A comparison between the two groups
10 was conducted in order to test whether there was a significant difference of AI or Side
11 Difference. In headache patients, the Asymmetry Index was compared with FIT visual
12 inspection by the doctor and with declarations of patient before each session (the side of pain
13 and intensity of pain using VAS scores).

16 **Results**

17 *Reliability of frontal infrared thermography*

18 FIT readings did not correlate with external factors during both during T1 and T2 sessions as
19 far as sex ($T_{\text{right}} r = 0.20, p = 0.24; T_{\text{left}} r = 0.23, p = 0.17$), room temperature ($T_{\text{right}} r =$
20 $0.22, p = 0.20; T_{\text{left}} r = 0.19, p = 0.27$) and age ($T_{\text{right}} r = -0.017, p = 0.92; T_{\text{left}} r = 0.035, p$
21 $= 0.83$) is concerned.

22 During each session, paired t-Test analysis revealed no significant difference between
23 consecutive FIT measurements during the same session ($p > 0.016$) for all the three
24 comparisons (m1 vs m2, m2 vs m3, m1 vs m3) in both the right and left measurement side
25 (Figure 3).

1 The reliability analysis demonstrated “excellent”¹⁴ results during T1 (ICC values: right side,
2 0.73; left side, 0.81). The same result was confirmed during T2 (ICC values: right side, 0.80;
3 left side, 0.74).

4 Regarding the reproducibility, mean CV between consecutive FIT measurements in the right
5 and left side were similar in controls (T1: left side: $1.63\% \pm 1.79$; right side: $1.69\% \pm 2.09$;
6 T2: left side: $2.71\% \pm 3.26$; right side: $2.67\% \pm 3.22$) and in patients (T1: left side: $3.77\% \pm$
7 3.57 ; right side: $3.87\% \pm 3.62$; T2: left side: $2.71\% \pm 3.26$; right side: $2.67\% \pm 3.22$).

8 However, in patients, CV range was slightly greater than in controls both in T1 and T2
9 session (patients: 0.00%-13.40%; controls: 0.00% - 10.04%). In addition, the average smallest
10 CV was observed among m2m3 measurements (m2m3: $1.56\% \pm 0.62$ vs m1m2: $3.13\% \pm 1.29$
11 and m1m3: $3.54\% \pm 1.25$). Despite this, the overall reproducibility of the measurements was
12 very good because the maximum CV was less than 13.40%.

13 When examining intra-subject variations between two different days (inter-test), CV
14 represents the percentage difference between two daily sessions (T1 and T2). The maximum
15 CVs between test sessions (T1 and T2) were very low (patients range: 0.19 - 8.24%, controls
16 range: 0.00 - 7.56%) thus suggesting a good reproducibility of the measurements over
17 different days.

18 The range of temperature was not different between days or between the two groups of
19 subjects (controls: T1: 33.10-36.73°C; T2: 34.13 – 36.70°C; patients: T1: 32.30 – 37.60; T2:
20 32.30 – 36.17°C). Patients were characterized by a larger standard deviation of temperature
21 than controls (Figure 3). The two-way ANOVA with replication over 35 subjects
22 demonstrated that there were no significant differences between FIT measurements in
23 different days.

24 ***Characterization of frontal infrared thermography comparing patients and controls***

1
2
3 1 In controls, the temperature measurements during T1 varied from a minimum of 32.60°C to a
4
5 2 maximum value of 38.90°C (mean on the two sides: 35.05°C, standard deviation: 1°C,
6
7 3 corresponding to 2.8% of the mean value). In patients with chronic migraine the temperature
8
9 4 measurements during T1 varied from a minimum of 31.90°C to a maximum value of 38.30°C
10
11 5 with a larger standard deviation from the mean than controls (mean on the two sides 35.47°C,
12
13 6 standard deviation 1.59°C, corresponding 4.5% of the mean value).

15
16 7 Whereas average AI was not different ($p>0.05$) between patients (-0.00002 ± 0.0164) and
17
18 8 controls (-0.00118 ± 0.0091), the Side Difference, representing the absolute value of the
19
20 9 difference between temperature measured in the left and right side, significantly discriminated
21
22 10 controls (mean \pm std: $0.73\% \pm 0.55$) from patients ([mean \pm SD]: $1.37\% \pm 0.87$, P-value one
23
24 11 tail <0.0001) (Fig. 4).

26
27 12 Conversely, AI can be used to locate the cold patch in patients. In fact, AI polarity (positive or
28
29 13 negative, where positive AI value means that the cold patch is located on the right side of the
30
31 14 forehead) was in consort with the visual inspection of the FIT by the examiner (correlation,
32
33 15 $r^2=0.7$, $p=0.00072$). In addition, when the patient referred a bilateral pain before the test
34
35 16 session, both the visual inspection and the AI index revealed an asymmetry in the forehead,
36
37 17 thus suggesting that the AI can be a reliable index for the localization of the coldpatch also
38
39 18 when the patient's perception is not reliable.

41
42 19 Finally, in patients with unilateral pain, the correlation between AI and the patient-referred
43
44 20 pain side before FIT was good ($r^2=0.6$, $p=0.0056$). Conversely, even though patients were
45
46 21 examined mainly during attacks with different pain severities, as measured by VAS, the
47
48 22 correlation between AI and pain severity was very low ($r^2=0.2$, $p=0.37$).

50
51 23

52 24 **Discussion**

1
2
3 1 In this study, we examined the usability and reproducibility of FIT measurement in patients
4
5 2 with headache and in healthy subjects, in a research scenario in which previous experience
6
7 3 using FIT were not conclusive^{1,3,4,6,7,18}.

8
9 4 In order to obtain comparable results between patients and controls, we used a thermal
10
11 5 punctual evaluation instead of an evaluation by area. In fact, whereas patients showed a cooler
12
13 6 area (the cold patch), controls did not, thus making the evaluation by area unreliable and not
14
15 7 reproducible. We therefore chose to evaluate the temperature in two symmetric points
16
17 8 equidistant from the nasion. In patients, one point was the coolest point in the cold patch, and
18
19 9 the second was its symmetric, in controls we took two symmetric points located on a circle of
20
21 10 fixed radius. With this setup, our data showed that FIT is a reproducible tool provided that
22
23 11 standard location and standard measurement procedure is carried out. In fact, we found good
24
25 12 reproducibility of the measurements within the same session and between the two sessions, as
26
27 13 measured by CV. However, we also found the smallest CV in the comparison between the
28
29 14 second reading and the third reading during each test sessions, while the first reading, even
30
31 15 though statistically not different from the others, cannot be always reliable during
32
33 16 thermography. Since the first reading was taken immediately when the patient entered the
34
35 17 room, it is likely that, after some minutes, there is some stabilization of the subject at the
36
37 18 room temperature that affects the absolute measurements. This observation suggests that a
38
39 19 stabilization period of the subject at the room temperature is recommended before the
40
41 20 thermograph exam in order to guarantee an effective measurement. [This is in line with](#)
42
43 21 [available guidelines suggesting that thermography measures should be taken after a](#)
44
45 22 [stabilization period of 15-20 minutes to allow equilibrating with the environment.](#)^{12,13}

46
47 23 Our data also suggest that FIT is a reliable procedure in detecting the cold patch location in
48
49 24 headache patients and that the AI parameter is able to localize the cold patch even when the
50
51 25 patient referred a bilateral pain before the image is recorded. In previous studies, no
52
53
54
55
56
57
58
59
60

1 correlation was found between FIT measurements and pain side or VAS score in patients^{5,18}.
2
3
4
5 1 Instead, our results demonstrate that the Asymmetry Index defined by Kurth et al.¹⁹ well
6
7 2 describe the lateralization of cold patch in patients. Moreover, AI index correlates with
8
9 3 doctor's visual inspection of FIT and in case of unilateral pain there is a good correlation
10
11 4 between AI and pain side. Even if the correlation between AI and VAS score is low, AI index
12
13 5 could be a useful tool in order to localize the pathological side (where there is the coldpatch)
14
15 6 in each patient. Our results further confirm that regardless to patient's perception, the cold
16
17 7 patch can be viewed as a "unilateral" entity, representing the neurochemical imbalance
18
19 8 between the two sides in terms of microcirculation in the facial district. This hypothesis is in
20
21 9 line with neurophysiological studies on Visual Evoked Potentials showing a prominent
22
23 10 laterality of neurophysiological signatures in headache²⁰⁻²⁴. Therefore, the AI estimated by
24
25 11 FIT can have a relevant prognostic role going beyond patient's perception.
26
27 12
28
29 13 Finally, the SideDifference parameter was able to discriminate headache patients from
30
31 14 controls, even if the FIT image was taken with patients experiencing different pain intensities.
32
33 15 These observations suggest that FIT can be a useful neurophysiological aid in the diagnosis
34
35 16 for pain medicine. An add-on marker in diagnosis may be useful in difficult case or when
36
37 17 there is a risk for diagnostic mistakes concerning unilateral or bilateral headaches form²⁶. We
38
39 18 foresee the time when FIT could be used in evaluating pharmacological and non-
40
41 19 pharmacological treatment in headache and other facial neuralgia: FIT with a commercially
42
43 20 available camera is a relatively inexpensive procedure that can be used in headache and pain
44
45 21 centre setting.
46
47
48 22 However, even though promising, our results were obtained in a relatively small number of
49
50 23 subjects, and acquisitions followed a shared protocol that guaranteed consistency across
51
52 24 subjects. Therefore, for future applications, it will be important to create a consensus
53
54 25 procedure for FIT acquisition, able to support diagnosis.

1 From a practical viewpoint, in the current therapeutic scenario, where non-invasive
2 neuromodulation techniques are increasingly used for the treatment of migraine [21–23][25–
3 27] , these results can reach an even more interesting meaning. In fact, transcranial direct
4 current stimulation (tDCS) has been proposed for the treatment of migraine^{27,28,30,31}. tDCS is
5 a non-invasive technique that acts sub-threshold (<1 V/m vs. 100 V/m produced by other
6 supra-threshold techniques³², producing an excitability change in the area below the electrode.
7 Even though the electric field induced by tDCS spread over neighbouring areas, the electrode
8 montage is a crucial element in the optimization of tDCS therapy²⁹. In migraine, electrodes
9 are usually placed in the frontal area, according to patient's perception and subjective
10 analysis. Conversely, the cold patch, representing a vasoconstriction area characterizing the
11 migraine may be an effective target for neuromodulation intervention. In migraine patients,
12 the cold patch corresponds to a vasoconstriction within the external carotid territory, which
13 represents the end result of the haemodynamic changes due to the activity of the autonomic
14 and the trigeminovascular systems. In this case, cathodal tDCS over this area may reduce the
15 pathological frontal asymmetry. For this reason, the automatic localization of cold patch using
16 FIT based parameters, as proposed in this study, can be applied for the optimization of tDCS
17 treatment in migraine patients.

18 Taken together, our results suggest that FIT could be useful as a diagnostic tool, to localize
19 the cold patch and to study of unilateral headache without side shift like Cluster Headache,
20 Paroxysmal Hemicrania, SUNCT or cranial neuralgias (trigeminal neuralgia). However, the
21 case series is relatively small in order to evaluate the sensitivity and specificity of FIT in
22 discriminating between different headache entities. In addition, even though at present there is
23 no strong evidence supporting the change of FIT after a pharmacological or non-
24 pharmacological treatment, the use tDCS or prophylactic agents (beta blockers, Calcium

1 antagonist) show a tendency to reducing or disappearing of FIT asymmetry, thus suggesting
2 the use of FIT also as a prognostic tool.

4 **Conclusions**

5 In conclusion, in respect to previous studies, this work introduces the possibility to use
6 modern commercial infrared thermal camera for the analysis of frontal thermography in
7 migraine patients. Moreover, two new parameters (AI and Side Difference) provided
8 meaningful results, being one able to localize the cold patch and the other one able to
9 distinguish patients from controls.

12 **Article Highlights**

- 13 • The use of Frontal Infrared Thermography (FIT) in the diagnosis of primary
14 headaches is still debated.
- 15 • In this study, we showed that FIT measurements have good reproducibility even when
16 using commercial cameras in both patients and controls.
- 17 • We defined a new parameter, the Side Difference, that is able to discriminate patients
18 with headache from controls.
- 19 • We defined another parameter, the Asimmetry Index, that correlates with the side of
20 pain.
- 21 • FIT can be used to characterize vascular changes in chronic migraine patients but
22 standardized recording conditions are needed to guarantee reliability.

1
2
3 **1 Funding resources**

4
5 2 This research did not receive any specific grant from funding agencies in the public,
6
7 3 commercial, or not-for-profit sectors.
8

9
10
11 **5 Institutional Review Board Approval:**

12
13 6 The study was approved by the institutional review board (Ethical Committee of the
14
15 7 Fondazione IRCCS Istituto Neurologico Nazionale Casimiro Mondino, date of approval: July
16
17 8 29th 2013) and conformed with the Declaration of Helsinki. All patients signed written
18
19 9 informed consent before participating to the study.
20
21

22
23 10

24 **11 Conflict of interest statement**

25
26 12 Elena Rossi, at the time of the work, was employed by Newronika Srl, a spin-off company of
27
28 13 the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and of the University of
29
30 14 Milan. Sara Marceglia is founder and shareholder of Newronika Srl.

31
32
33 15 The other authors declare no conflict.
34

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 16

1 **References**

- 2 1. Szentkuti A, Kavanagh HS, Grazio S. Infrared thermography and image analysis for
3 biomedical use. *Period Biol* 2011; 113: 385–392.
- 4 2. Haddad DS, Brioschi ML, Baladi MG, et al. A new evaluation of heat distribution on
5 facial skin surface by infrared thermography. *Dentomaxillofacial Radiol* 2016; 45:
6 20150264.
- 7 3. Swerdlow B, Dieter JN. The Validity of the Vascular ‘Cold Patch’ in the Diagnosis of
8 Chronic Headache. *Headache J Head Face Pain* 1986; 26: 22–26.
- 9 4. Edmeads J. Is thermography a marker for vascular headaches? *Headache* 1986; 26: 47.
- 10 5. Swerdlow B, Dieter JN. The vascular ‘cold patch’ is not a prognostic index for
11 headache. *Headache* 1989; 29: 562–568.
- 12 6. Dalla Volta G, Anzola GP. Are There Objective Criteria to Follow Up Migrainous
13 Patients? A Prospective Study with Thermography and Evoked Potentials. *Headache J*
14 *Head Face Pain* 1988; 28: 423–425.
- 15 7. Dalla Volta G, Anzola GP, DiMonda V. The disappearance of the ‘cold patch’ in
16 recovered migraine patients: thermographic findings. *Headache* 1991; 31: 305–309.
- 17 8. Drummond PD, Lance JW. Facial temperature in migraine, tension-vascular and tension
18 headache. *Cephalalgia Int J Headache* 1984; 4: 149–158.
- 19 9. Drummond PD, Lance JW. Thermographic changes in cluster headache. *Neurology*
20 1984; 34: 1292–1298.
- 21 10. Zaproudina N, Närhi M, Lipponen JA, et al. Nitroglycerin-induced changes in facial skin
22 temperature: ‘cold nose’ as a predictor of headache? *Clin Physiol Funct Imaging* 2013;
23 n/a-n/a.
- 24 11. Headache Classification Committee of the International Headache Society (IHS). The
25 International Classification of Headache Disorders, 3rd edition (beta version).
26 *Cephalalgia Int J Headache* 2013; 33: 629–808.
- 27 12. American Academy of Thermology. Guidelines for neuro-musculoskeletal infrared
28 medical thermography and sympathetic skin response (SSR) studies,
29 [https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-](https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-musculoskeletal-thermography/)
30 [musculoskeletal-thermography/](https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-musculoskeletal-thermography/) (accessed 12 June 2018).
- 31 13. Schwartz RG, Getson P, O’Young B, et al. Guidelines for Dental-Oral and Systemic
32 Health Infrared Thermography. *Pan Am J Med Thermol* 2015; 2: 44–53.
- 33 14. Fleiss JL. *The Design and Analysis of Clinical Experiments: Fleiss/The Design*.
34 Hoboken, NJ, USA: John Wiley & Sons, Inc. Epub ahead of print 8 February 1999.
35 DOI: 10.1002/9781118032923.
- 36 15. Lexell JE, Downham DY. How to assess the reliability of measurements in
37 rehabilitation. *Am J Phys Med Rehabil* 2005; 84: 719–723.

- 1
2
3 1 16. Antonaci F, Sand T, Lucas GA. Pressure algometry in healthy subjects: inter-examiner
4 2 variability. *Scand J Rehabil Med* 1998; 30: 3–8.
- 5
6 3 17. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol*
7 4 *Bull* 1979; 86: 420–428.
- 8
9 5 18. Ford R, Ford K. Thermography in the Diagnosis of Headache. *Semin Neurol* 1997; 17:
10 6 343–349.
- 11
12 7 19. Kurth F, Gaser C, Luders E. A 12-step user guide for analyzing voxel-wise gray matter
13 8 asymmetries in statistical parametric mapping (SPM). *Nat Protoc* 2015; 10: 293–304.
- 14
15 9 20. Anzola GP, Dalla Volta G, Di Monda V, et al. Laterality Indexes In Primary Headache :
16 10 Teletermography, Visual Evoked Potentials, Reaction Times. *Cephalalgia* 1987; 7: 301–
17 11 301.
- 18
19 12 21. Kudrow L. Thermographic and Doppler Flow Asymmetry in Cluster Headache.
20 13 *Headache J Head Face Pain* 1979; 19: 204–208.
- 21
22 14 22. Gawel M, Connolly JF, Rose FC. Migraine Patients Exhibit Abnormalities in the Visual
23 15 Evoked Potential. *Headache J Head Face Pain* 1983; 23: 49–52.
- 24
25 16 23. Raudino F. Visual evoked potential in patients with migraine. *Headache* 1988; 28: 531–
26 17 533.
- 27
28 18 24. Boylu E, Domaç FM, Koçer A, et al. Visual evoked potential abnormalities in migraine
29 19 patients. *Electromyogr Clin Neurophysiol* 2010; 50: 303–308.
- 30
31 20 25. Drummond PD. Vascular Changes in Atypical Facial Pain. *Headache J Head Face Pain*
32 21 1988; 28: 121–123.
- 33
34 22 26. Voiticovschi-Iosob C, Allena M, De Cillis I, et al. Diagnostic and therapeutic errors in
35 23 cluster headache: a hospital-based study. *J Headache Pain* 2014; 15: 56.
- 36
37 24 27. Antal A, Kriener N, Lang N, et al. Cathodal transcranial direct current stimulation of the
38 25 visual cortex in the prophylactic treatment of migraine. *Cephalalgia Int J Headache*
39 26 2011; 31: 820–828.
- 40
41 27 28. Dasilva AF, Mendonca ME, Zaghi S, et al. tDCS-induced analgesia and electrical fields
42 28 in pain-related neural networks in chronic migraine. *Headache* 2012; 52: 1283–1295.
- 43
44 29 29. DaSilva AF, Truong DQ, DosSantos MF, et al. State-of-art neuroanatomical target
45 30 analysis of high-definition and conventional tDCS montages used for migraine and pain
46 31 control. *Front Neuroanat* 2015; 9: 89.
- 47
48 32 30. Magis D. Neuromodulation in migraine: state of the art and perspectives. *Expert Rev*
49 33 *Med Devices* 2015; 12: 329–339.
- 50
51 34 31. Viganò A, D’Elia TS, Sava SL, et al. Transcranial Direct Current Stimulation (tDCS) of
52 35 the visual cortex: a proof-of-concept study based on interictal electrophysiological
53 36 abnormalities in migraine. *J Headache Pain* 2013; 14: 23.

- 1
2
3 1 32. Dmochowski JP, Datta A, Bikson M, et al. Optimized multi-electrode stimulation
4 2 increases focality and intensity at target. *J Neural Eng* 2011; 8: 046011.

5
6 3 **Figures legends**

7
8 4 **Figure 1-** Measurement point identification in patients. The radius of the circle was calculated
9
10 5 as the distance between the Nasion and the coolest point in the cold patch. Once defined the
11
12 6 radius, the second point was the point equidistant from the Nasion and with the same vertical
13
14 7 coordinate of the first point of measurement (symmetric point).
15

16 8
17
18 9 **Figure 2-** Measurement point identification in controls. The radius of the circle was constant.
19

20
21 10
22
23 11 **Figure 3 –** Mean FIT measured over 20 controls (left side) and 15 patients (right side) in
24
25 12 three consecutive readings (m1, m2, m3 - x axis) with 10 minutes of rest between readings
26
27 13 during T1 and T2. Error bars represent standard errors.
28

29 14
30
31 15 **Figure 4 -** Difference between left and right side as a percentage of the average temperature
32
33 16 in forehead (SideDifference) in patients (N=20) and controls (N=15).
34
35

36 17
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Frontal infrared thermography in healthy individuals and chronic**
2 **migraine patients: reliability of the method**

3
4 Fabio Antonaci, MD, PhD¹, Elena Rossi, PhD^{2,3}, Cristina Voiticovschi-Iosob, MD⁴, Giorgio
5 Dalla Volta, MD⁵, and Sara Marceglia, PhD^{6*}

6
7 ¹*Headache Centre, C. Mondino National Institute of Neurology Foundation, IRCCS,*
8 *Department of Brain and Behavioral Sciences University of Pavia, Italy.*

9 ²*Dipartimento di Elettronica, Informazione e Bioingegneria. Politecnico di Milano. Milan,*
10 *Italy.*

11 ³*Newronika srl, Milan, Italy*

12 ⁴*State Medical and Pharmaceutical University “Nicolae Testemitanu”, Chisinau, Moldova.*

13 ⁵*U.O Neurologia, Istituto Clinico Città di Brescia, Brescia, Italy.*

14 ⁶*Dipartimento di Ingegneria e Architettura. Università degli Studi di Trieste. Trieste, Italy.*

15
16 * Corresponding author

17 Dipartimento di Ingegneria e Architettura, Università degli Studi di Trieste, via A. Valerio 10,
18 34127 Trieste, ITALIA

19 tel: +39 040 558 3450

20 email: smarceglia@units.it

21
22 **Keywords**

23 Frontal Thermography (FIT); Chronic Migraine; Cold Patch; Standard Procedure; Reliability

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abbreviations**

2 2 AI – Asymmetry Index

3 3 ANOVA – analysis of variance

4 4 BMS - between-subjects mean square

5 5 CV - Coefficient of Variation

6 6 EMS - residual mean square

7 7 FIT – Frontal Infrared Thermography

8 8 ICC - intra-class correlation coefficient

9 9 JMS - within-subjects mean square

10 10 tDCS - transcranial direct current stimulation

11 11 VAS - Visual Analogue Scale

12

13

14

1
2
3 1 **Abstract**

4
5 2 **Background:** The use of Frontal infrared thermography in the diagnosis of primary
6
7 3 headaches provided scattering results due to measurement fluctuations and different types of
8
9 4 headaches or research protocols.

10
11 5 **Objective:** This study aims to assess the reliability of Frontal infrared thermography in
12
13 6 healthy individuals and provide a preliminary evaluation in chronic migraine patients using a
14
15 7 commercial infrared thermal camera.

16
17
18 8 **Methods:** Thermographic images were acquired in 20 controls and 15 patients at 3
19
20 9 consecutive time-points in two daily sessions. The Side Difference and Asymmetry Index
21
22 10 parameters were defined. The reproducibility of the measurements, the correlation of
23
24 11 Asymmetry Index and Side Difference with clinical evaluations and patient perceptions, and
25
26 12 the ability of the parameters to discriminate between patients and controls were investigated.

27
28
29 13 **Results:** We reported a good reproducibility of the measurements (Inter-class Correlation
30
31 14 Coefficient >0.75 and Coefficient of Variation $<13.4\%$), independent from external factors.
32
33 15 The Side Difference was significantly different between patients and controls ($p<0.001$). The
34
35 16 Asymmetry Index showed good correlation with the side of unilateral pain ($p=0.0056$).

36
37 17 **Conclusions:** Frontal infrared thermography can be used to quantify the difference between
38
39 18 the right and the left side of frontal vascular changes in chronic migraine patients, provided
40
41 19 that standardized conditions are satisfied.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

2 Infrared Thermography detects infrared light emitted by the human body to visualize changes
3 in heat due to abnormalities in the skin surface blood flow of diseased areas. This non-
4 invasive and non-radiative imaging technique has different clinical applications including the
5 detection of circulatory and/or inflammatory disorders such as rheumatoid arthritis,
6 Raynaud's disease or osteoarthritis of the knee¹. It was also demonstrated that thermography
7 is able to capture thermal gradient in facial areas characterizing healthy individuals².

8 However, the literature investigating the use of external carotid region (forehead) thermal
9 imaging for the characterization of vascular headaches did not reach consistent results due to
10 different types of headache evaluated, different timing of patients' evaluation (during
11 headache attack or in headache free interval), different technologies used for image
12 acquisition, and different methods for imaging or statistical analysis.

13 In 1986, Swerdlow and Dieter³ comparing electronic thermography between 275 headache
14 patients and 45 controls, defined the "Cold Patch" as a region of the face where the
15 temperature is cooler (less than 0.5°C) than the surrounding areas^{3,4}. The presence of the cold
16 patch is more frequent in vascular headaches than in healthy subjects or patients with tension
17 type headache, psychogenic headaches or post-traumatic headaches.

18 There is an open question on whether the cold patch is a "fixed" entity⁵ or whether it
19 decreases with therapy^{6,7}. In fact, whereas according to Swerdlow and Dieter, "the vascular
20 cold patch is independent of prognosis and is most likely a permanent element of a vascular
21 headache sufferer's facial thermal pattern"⁵, in 1991, Dalla Volta et al.⁷ suggested that the
22 "cold patch" in vascular headache patients is ipsilateral to the prevailing side of pain and that
23 the cooler area decreased after 6 months of prophylactic therapy. The differences observed by
24 the two groups may be explained in terms of experimental protocol and patient's selection
25 that introduced a higher variability in the cold patch response⁷.

1
2
3 1 Anyway, there is large consensus on the fact that the cold patch represents an asymmetry in
4
5 2 the forehead of migraine patients. Unfortunately, the location of the cold patch is seldom
6
7 3 related to the side of the pain⁵ probably due to the variation of temperature during headache
8
9 4 attack or due to the lateralization of the headache (unilateral or bilateral) as measured by
10
11 5 Drummond and Lance^{8,9}.

12
13 6 Finally, FIT, in conjunction with nitroglycerine administration, was suggested as a novel non-
14
15 7 invasive approach to study vascular processes underlying headaches¹⁰.

16
17
18 8 Taken together, all these studies demonstrate that FIT can be used as diagnostic tool in
19
20 9 migraine with and without aura, in cluster headache and in other headache types.

21
22 10 In the light of previous observations and of new possible therapeutic applications, the present
23
24 11 study has two primary end points: (1) to evaluate the reliability of FIT measurements in
25
26 12 controls and chronic migraine patients using modern commercial infrared thermal camera; (2)
27
28 13 to verify whether FIT-based parameters correlate both with the visual evaluation of FIT by an
29
30 14 expert clinician and with patient's perception of pain side (at least in case of unilateral pain).

31
32
33 15

34 35 16 **Materials and methods**

36 37 17 *Subjects*

38
39 18 Thirty five right handed volunteers (26 females and 9 males) with a mean age of 35±11.6
40
41 19 years (range: 20-55) were enrolled at the Headache centre of the Fondazione IRCCS Istituto
42
43 20 Neurologico Nazionale Casimiro Mondino. All the subjects were not medicated at the time of
44
45 21 testing.

46
47
48 22 15 of the 35 volunteers (3 males) suffered from chronic migraine with medication overuse, as
49
50 23 assessed according to the IHS Classification¹¹. They were examined while hospitalized and
51
52 24 during a washout period from analgesics or other symptomatic treatment, including non-
53
54 25 headache medication. Patients were not on dietary/smoking restrictions ahead of

1
2
3 1 measurements. Patients did not use preventive treatment and underwent daily parenteral
4
5 2 detoxification (saline, cyanocobalamin, folic acid, nicotinamide, glutathione, delorazepam
6
7 3 and metoclopramide on demand). Patients were assessed on the second or third day after
8
9 4 symptomatic medication withdrawal that started on the day of hospital admission. No
10
11 5 symptomatic medication was allowed during the evaluation period but local ice bag (at least
12
13 6 one day apart from the examination). Hence, patients were generally with headache during the
14
15 7 examination. Pain severity was evaluated before each examination on a 0-3-score Visual
16
17 8 Analogue Scale (0: no pain, 1: mild pain, 2: moderate pain 3: severe pain) with a mean value
18
19 9 of [mean±SE] 1.88 ± 0.078 .

20
21
22 10 The remaining 20 of the 35 volunteers were used as controls since they suffered from
23
24 11 migraine or tension type headache no more than 1-2 times a year.

25
26 12 The study was approved by the institutional review board (Ethical Committee of the
27
28 13 Fondazione IRCCS Istituto Neurologico Nazionale Casimiro Mondino, date of approval: July
29
30 14 29th 2013) and conformed with the Declaration of Helsinki. All patients signed written
31
32 15 informed consent before participating to the study.

33 34 35 16 ***Frontal Infrared Thermography***

36
37 17 FIT was assessed with a modern infrared thermal camera (model LT3, produced by Zhejiang
38
39 18 Dali Technology Co. Ltd) characterized by a thermal sensitivity below 0.08°C at 30°C ,
40
41 19 according to suggested guidelines^{12,13}. FIT measured the spatial distribution of the heat over
42
43 20 the human face (object emissivity 0.98): the camera was placed at distance of 1 meter from
44
45 21 the subject in a room with stable temperature ($23.6 \pm 1.57^{\circ}\text{C}$). To ensure comparability
46
47 22 between patients and controls, since controls do not have a “cold area”, the temperature was
48
49 23 evaluated in two target points (left and right side) in the frontal polar sites. In patients, we
50
51 24 identified the coolest point in the side showing the cold patch, and then we identified its
52
53 25 symmetric on the other side of the head (equidistant from the nasion, Fig.1). In controls there
54
55
56
57
58
59
60

1 is no cold patch, so we used two symmetric points equidistant from the nasion on a radius of
2 2cm (Fig.2). This protocol allowed repeatability and comparability among subjects.

3 ***Study design***

4 All measurements were taken in two test sessions (T1 and T2) for all subjects. The second
5 session (T2) was run at least one day apart in order to evaluate the intra-subject variations in
6 FIT. During each session (T1 and T2), the measurements were repeated three times (m1, m2,
7 m3) by the same experimenter after 10 minutes of rest between each measurement. Room
8 temperature was recorded during each session. Images were taken approximately at the same
9 time of the day in each patient (10-12 a.m. or 2.00-4.00 p.m.).

11 ***Data analysis***

12 *Reliability of Frontal Thermography (FIT)*

13 In order to verify whether measurements were influenced by external factors, correlation
14 analysis was computed with respect to room temperature, sex and age of subjects, both at T1
15 and at T2, using m1, m2, and m3 as dependent variables.

16 Student's paired t-Test was used to determine whether three measurements belonging to the
17 same session (m1 vs m2, m2 vs m3, m1 vs m3) had the same mean. The Bonferroni
18 correction for repeated measures was applied ($p < 0.016$).

19 Reliability of measurements was investigated using the intra-class correlation coefficient
20 (ICC), defined as the fraction of variance that is caused by the variation between subjects.

21 Thus, if the variance between tests is smaller than the variance between subjects then ICC is
22 close to 1. According to Fleiss, ICC values above 0.75 generally mean "excellent"
23 reliability¹⁴. The intra-class correlation coefficient (ICC) was calculated for FIT at each point:
24 data during a single session (T1 and T2) were analysed using a Two Factor ANOVA without

1
2
3 1 Replication (factors: subjects and FIT readings m_i) and the value from the analysis of variance
4
5 2 table were substituted into equation (1):

$$3 \quad ICC_{2,1} = (BMS - EMS) / (BMS + EMS + 2(JMS - EMS) / n) \quad (1)$$

8
9 4 where BMS is the between-subjects mean square, EMS is the residual mean square, JMS is
10
11 5 the within-subjects mean square, n is number of subjects¹⁵.

13 6 The reproducibility of the method was tested by calculating the Coefficient of Variation (CV)
14
15 7 during the first test session^{16,17}. For each comparison between measurements (m_1 vs m_2 , m_2
16
17 8 vs m_3 , m_1 vs m_3) the coefficient of variation (equation 2) was calculated as the absolute
18
19 9 value of:

$$22 \quad CV = 100 * | (m_i - m_{i+1}) / ((m_i + m_{i+1}) / 2) | \quad (2)$$

24 11 where m_i is the first reading (test) and m_{i+1} is the second one (retest). The numerator is the
25
26 12 difference between two consecutive measurements and the denominator is the average of the
27
28 13 two measurements. In this way, the Coefficient of Variation is the percentage difference
29
30 14 between two readings. For each subject the coefficient of variation was computed for the three
31
32 15 intra-session comparisons and then averaged across subjects.

35 16 In order to evaluate the intra-subject variations in FIT, a two-way analysis of variance with
36
37 17 replication (2-way ANOVA) was performed for a statistical comparison between two
38
39 18 different test sessions (T1 and T2).

41 19 *Characterization of images comparing controls and patients*

43
44 20 In order to verify the difference between migraine FIT measurement and healthy subject FIT
45
46 21 measurements, we defined two parameters:

- 48 22 ■ the Asymmetry Index [14] (equation 3)

$$50 \quad 23 \quad AI = 2 \times ((T_{left} - T_{right}) / (T_{left} + T_{right})) \quad (3)$$

52 24 Where T_{left} is the temperature on the left forehead and T_{right} is the temperature of the right
53
54 25 forehead. AI was calculated in order to assess the lateralization of FIT. If the temperature

1 measurement on the two sides is the same, then the asymmetry index is equal to 0. Positive AI
2 value means that the cold patch is located on the right side of the forehead. Conversely, a
3 negative asymmetry index means a lateralization on the left side.

4 ▪ the absolute value of percentage difference between left and right side

$$5 \text{ Side Difference (\%)} = 100 * | 2 * (T_{\text{left}} - T_{\text{right}} / T_{\text{left}} + T_{\text{right}}) | \quad (4)$$

6 SideDifference (equation 4) is the difference between left and right side as a percentage of the
7 average temperature in forehead.

8 Both parameters were calculated from all the measurements of each patients (15*6=90
9 observations) and controls (20*6=120 observations). A comparison between the two groups
10 was conducted in order to test whether there was a significant difference of AI or Side
11 Difference. In headache patients, the Asymmetry Index was compared with FIT visual
12 inspection by the doctor and with declarations of patient before each session (the side of pain
13 and intensity of pain using VAS scores).

16 **Results**

17 *Reliability of frontal infrared thermography*

18 FIT readings did not correlate with external factors during both during T1 and T2 sessions as
19 far as sex ($T_{\text{right}} r = 0.20, p = 0.24; T_{\text{left}} r = 0.23, p = 0.17$), room temperature ($T_{\text{right}} r =$
20 $0.22, p = 0.20; T_{\text{left}} r = 0.19, p = 0.27$) and age ($T_{\text{right}} r = -0.017, p = 0.92; T_{\text{left}} r = 0.035, p$
21 $= 0.83$) is concerned.

22 During each session, paired t-Test analysis revealed no significant difference between
23 consecutive FIT measurements during the same session ($p > 0.016$) for all the three
24 comparisons (m1 vs m2, m2 vs m3, m1 vs m3) in both the right and left measurement side
25 (Figure 3).

1
2
3 1 The reliability analysis demonstrated “excellent”¹⁴ results during T1 (ICC values: right side,
4 0.73; left side, 0.81). The same result was confirmed during T2 (ICC values: right side, 0.80;
5 0.74).
6
7
8

9 4 Regarding the reproducibility, mean CV between consecutive FIT measurements in the right
10 and left side were similar in controls (T1: left side: $1.63\% \pm 1.79$; right side: $1.69\% \pm 2.09$;
11 T2: left side: $2.71\% \pm 3.26$; right side: $2.67\% \pm 3.22$) and in patients (T1: left side: $3.77\% \pm$
12 3.57 ; right side: $3.87\% \pm 3.62$; T2: left side: $2.71\% \pm 3.26$; right side: $2.67\% \pm 3.22$).
13
14
15
16
17

18 8 However, in patients, CV range was slightly greater than in controls both in T1 and T2
19 session (patients: 0.00%-13.40%; controls: 0.00% - 10.04%). In addition, the average smallest
20 CV was observed among m2m3 measurements (m2m3: $1.56\% \pm 0.62$ vs m1m2: $3.13\% \pm 1.29$
21 and m1m3: $3.54\% \pm 1.25$). Despite this, the overall reproducibility of the measurements was
22 very good because the maximum CV was less than 13.40%.
23
24
25
26
27

28 13 When examining intra-subject variations between two different days (inter-test), CV
29 represents the percentage difference between two daily sessions (T1 and T2). The maximum
30 CVs between test sessions (T1 and T2) were very low (patients range: 0.19 - 8.24%, controls
31 range: 0.00 - 7.56%) thus suggesting a good reproducibility of the measurements over
32 different days.
33
34
35
36
37
38

39 18 The range of temperature was not different between days or between the two groups of
40 subjects (controls: T1: 33.10-36.73°C; T2: 34.13 – 36.70°C; patients: T1: 32.30 – 37.60; T2:
41 32.30 – 36.17°C). Patients were characterized by a larger standard deviation of temperature
42 than controls (Figure 3). The two-way ANOVA with replication over 35 subjects
43 demonstrated that there were no significant differences between FIT measurements in
44 different days.
45
46
47
48
49
50
51

52 24 ***Characterization of frontal infrared thermography comparing patients and controls***
53
54
55
56
57
58
59
60

1 In controls, the temperature measurements during T1 varied from a minimum of 32.60°C to a
2 maximum value of 38.90°C (mean on the two sides: 35.05°C, standard deviation: 1°C,
3 corresponding to 2.8% of the mean value). In patients with chronic migraine the temperature
4 measurements during T1 varied from a minimum of 31.90°C to a maximum value of 38.30°C
5 with a larger standard deviation from the mean than controls (mean on the two sides 35.47°C,
6 standard deviation 1.59°C, corresponding 4.5% of the mean value).

7 Whereas average AI was not different ($p > 0.05$) between patients (-0.00002 ± 0.0164) and
8 controls (-0.00118 ± 0.0091), the Side Difference, representing the absolute value of the
9 difference between temperature measured in the left and right side, significantly discriminated
10 controls (mean \pm std: $0.73\% \pm 0.55$) from patients ([mean \pm SD]: $1.37\% \pm 0.87$, P-value one
11 tail < 0.0001) (Fig. 4).

12 Conversely, AI can be used to locate the cold patch in patients. In fact, AI polarity (positive or
13 negative, where positive AI value means that the cold patch is located on the right side of the
14 forehead) was in consort with the visual inspection of the FIT by the examiner (correlation,
15 $r^2 = 0.7$, $p = 0.00072$). In addition, when the patient referred a bilateral pain before the test
16 session, both the visual inspection and the AI index revealed an asymmetry in the forehead,
17 thus suggesting that the AI can be a reliable index for the localization of the coldpatch also
18 when the patient's perception is not reliable.

19 Finally, in patients with unilateral pain, the correlation between AI and the patient-referred
20 pain side before FIT was good ($r^2 = 0.6$, $p = 0.0056$). Conversely, even though patients were
21 examined mainly during attacks with different pain severities, as measured by VAS, the
22 correlation between AI and pain severity was very low ($r^2 = 0.2$, $p = 0.37$).

23

24 Discussion

1
2
3 1 In this study, we examined the usability and reproducibility of FIT measurement in patients
4
5 2 with headache and in healthy subjects, in a research scenario in which previous experience
6
7 3 using FIT were not conclusive^{1,3,4,6,7,18}.

8
9 4 In order to obtain comparable results between patients and controls, we used a thermal
10
11 5 punctual evaluation instead of an evaluation by area. In fact, whereas patients showed a cooler
12
13 6 area (the cold patch), controls did not, thus making the evaluation by area unreliable and not
14
15 7 reproducible. We therefore chose to evaluate the temperature in two symmetric points
16
17 8 equidistant from the nasion. In patients, one point was the coolest point in the cold patch, and
18
19 9 the second was its symmetric, in controls we took two symmetric points located on a circle of
20
21 10 fixed radius. With this setup, our data showed that FIT is a reproducible tool provided that
22
23 11 standard location and standard measurement procedure is carried out. In fact, we found good
24
25 12 reproducibility of the measurements within the same session and between the two sessions, as
26
27 13 measured by CV. However, we also found the smallest CV in the comparison between the
28
29 14 second reading and the third reading during each test sessions, while the first reading, even
30
31 15 though statistically not different from the others, cannot be always reliable during
32
33 16 thermography. Since the first reading was taken immediately when the patient entered the
34
35 17 room, it is likely that, after some minutes, there is some stabilization of the subject at the
36
37 18 room temperature that affects the absolute measurements. This observation suggests that a
38
39 19 stabilization period of the subject at the room temperature is recommended before the
40
41 20 thermograph exam in order to guarantee an effective measurement. This is in line with
42
43 21 available guidelines suggesting that thermography measures should be taken after a
44
45 22 stabilization period of 15-20 minutes to allow equilibrating with the environment.^{12,13}

46
47 23 Our data also suggest that FIT is a reliable procedure in detecting the cold patch location in
48
49 24 headache patients and that the AI parameter is able to localize the cold patch even when the
50
51 25 patient referred a bilateral pain before the image is recorded. In previous studies, no
52
53
54
55
56
57
58
59
60

1 correlation was found between FIT measurements and pain side or VAS score in patients^{5,18}.
2
3
4
5 1 Instead, our results demonstrate that the Asymmetry Index defined by Kurth et al.¹⁹ well
6
7 2 describe the lateralization of cold patch in patients. Moreover, AI index correlates with
8
9 3 doctor's visual inspection of FIT and in case of unilateral pain there is a good correlation
10
11 4 between AI and pain side. Even if the correlation between AI and VAS score is low, AI index
12
13 5 could be a useful tool in order to localize the pathological side (where there is the coldpatch)
14
15 6 in each patient. Our results further confirm that regardless to patient's perception, the cold
16
17 7 patch can be viewed as a "unilateral" entity, representing the neurochemical imbalance
18
19 8 between the two sides in terms of microcirculation in the facial district. This hypothesis is in
20
21 9 line with neurophysiological studies on Visual Evoked Potentials showing a prominent
22
23 10 laterality of neurophysiological signatures in headache²⁰⁻²⁴. Therefore, the AI estimated by
24
25 11 FIT can have a relevant prognostic role going beyond patient's perception.
26
27 12
28
29 13 Finally, the SideDifference parameter was able to discriminate headache patients from
30
31 14 controls, even if the FIT image was taken with patients experiencing different pain intensities.
32
33 15 These observations suggest that FIT can be a useful neurophysiological aid in the diagnosis
34
35 16 for pain medicine. An add-on marker in diagnosis may be useful in difficult case or when
36
37 17 there is a risk for diagnostic mistakes concerning unilateral or bilateral headaches form²⁶. We
38
39 18 foresee the time when FIT could be used in evaluating pharmacological and non-
40
41 19 pharmacological treatment in headache and other facial neuralgia: FIT with a commercially
42
43 20 available camera is a relatively inexpensive procedure that can be used in headache and pain
44
45 21 centre setting.
46
47
48 22 However, even though promising, our results were obtained in a relatively small number of
49
50 23 subjects, and acquisitions followed a shared protocol that guaranteed consistency across
51
52 24 subjects. Therefore, for future applications, it will be important to create a consensus
53
54 25 procedure for FIT acquisition, able to support diagnosis.

1
2
3 1 From a practical viewpoint, in the current therapeutic scenario, where non-invasive
4
5 2 neuromodulation techniques are increasingly used for the treatment of migraine [21–23][25–
6
7 3 27] , these results can reach an even more interesting meaning. In fact, transcranial direct
8
9 4 current stimulation (tDCS) has been proposed for the treatment of migraine^{27,28,30,31}. tDCS is
10
11 5 a non-invasive technique that acts sub-threshold (<1 V/m vs. 100 V/m produced by other
12
13 6 supra-threshold techniques³², producing an excitability change in the area below the electrode.
14
15 7 Even though the electric field induced by tDCS spread over neighbouring areas, the electrode
16
17 8 montage is a crucial element in the optimization of tDCS therapy²⁹. In migraine, electrodes
18
19 9 are usually placed in the frontal area, according to patient's perception and subjective
20
21 10 analysis. Conversely, the cold patch, representing a vasoconstriction area characterizing the
22
23 11 migraine may be an effective target for neuromodulation intervention. In migraine patients,
24
25 12 the cold patch corresponds to a vasoconstriction within the external carotid territory, which
26
27 13 represents the end result of the haemodynamic changes due to the activity of the autonomic
28
29 14 and the trigeminovascular systems. In this case, cathodal tDCS over this area may reduce the
30
31 15 pathological frontal asymmetry. For this reason, the automatic localization of cold patch using
32
33 16 FIT based parameters, as proposed in this study, can be applied for the optimization of tDCS
34
35 17 treatment in migraine patients.
36
37
38
39 18 Taken together, our results suggest that FIT could be useful as a diagnostic tool, to localize
40
41 19 the cold patch and to study of unilateral headache without side shift like Cluster Headache,
42
43 20 Paroxysmal Hemicrania, SUNCT or cranial neuralgias (trigeminal neuralgia). However, the
44
45 21 case series is relatively small in order to evaluate the sensitivity and specificity of FIT in
46
47 22 discriminating between different headache entities. In addition, even though at present there is
48
49 23 no strong evidence supporting the change of FIT after a pharmacological or non-
50
51 24 pharmacological treatment, the use tDCS or prophylactic agents (beta blockers, Calcium
52
53
54
55
56
57
58
59
60

1 antagonist) show a tendency to reducing or disappearing of FIT asymmetry, thus suggesting
2 the use of FIT also as a prognostic tool.

4 **Conclusions**

5 In conclusion, in respect to previous studies, this work introduces the possibility to use
6 modern commercial infrared thermal camera for the analysis of frontal thermography in
7 migraine patients. Moreover, two new parameters (AI and Side Difference) provided
8 meaningful results, being one able to localize the cold patch and the other one able to
9 distinguish patients from controls.

12 **Article Highlights**

- 13 • The use of Frontal Infrared Thermography (FIT) in the diagnosis of primary
14 headaches is still debated.
- 15 • In this study, we showed that FIT measurements have good reproducibility even when
16 using commercial cameras in both patients and controls.
- 17 • We defined a new parameter, the Side Difference, that is able to discriminate patients
18 with headache from controls.
- 19 • We defined another parameter, the Asimmetry Index, that correlates with the side of
20 pain.
- 21 • FIT can be used to characterize vascular changes in chronic migraine patients but
22 standardized recording conditions are needed to guarantee reliability.

1
2
3 **1 Funding resources**

4
5 2 This research did not receive any specific grant from funding agencies in the public,
6
7 3 commercial, or not-for-profit sectors.
8

9
10
11 **5 Institutional Review Board Approval:**

12
13 6 The study was approved by the institutional review board (Ethical Committee of the
14
15 7 Fondazione IRCCS Istituto Neurologico Nazionale Casimiro Mondino, date of approval: July
16
17 8 29th 2013) and conformed with the Declaration of Helsinki. All patients signed written
18
19 9 informed consent before participating to the study.
20
21

22
23
24 **11 Conflict of interest statement**

25
26 12 Elena Rossi, at the time of the work, was employed by Newronika Srl, a spin-off company of
27
28 13 the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and of the University of
29
30 14 Milan. Sara Marceglia is founder and shareholder of Newronika Srl.

31
32
33 15 The other authors declare no conflict.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 References

- 2 1. Szentkuti A, Kavanagh HS, Grazio S. Infrared thermography and image analysis for
3 biomedical use. *Period Biol* 2011; 113: 385–392.
- 4 2. Haddad DS, Brioschi ML, Baladi MG, et al. A new evaluation of heat distribution on
5 facial skin surface by infrared thermography. *Dentomaxillofacial Radiol* 2016; 45:
6 20150264.
- 7 3. Swerdlow B, Dieter JN. The Validity of the Vascular ‘Cold Patch’ in the Diagnosis of
8 Chronic Headache. *Headache J Head Face Pain* 1986; 26: 22–26.
- 9 4. Edmeads J. Is thermography a marker for vascular headaches? *Headache* 1986; 26: 47.
- 10 5. Swerdlow B, Dieter JN. The vascular ‘cold patch’ is not a prognostic index for
11 headache. *Headache* 1989; 29: 562–568.
- 12 6. Dalla Volta G, Anzola GP. Are There Objective Criteria to Follow Up Migrainous
13 Patients? A Prospective Study with Thermography and Evoked Potentials. *Headache J*
14 *Head Face Pain* 1988; 28: 423–425.
- 15 7. Dalla Volta G, Anzola GP, DiMonda V. The disappearance of the ‘cold patch’ in
16 recovered migraine patients: thermographic findings. *Headache* 1991; 31: 305–309.
- 17 8. Drummond PD, Lance JW. Facial temperature in migraine, tension-vascular and tension
18 headache. *Cephalalgia Int J Headache* 1984; 4: 149–158.
- 19 9. Drummond PD, Lance JW. Thermographic changes in cluster headache. *Neurology*
20 1984; 34: 1292–1298.
- 21 10. Zaproudina N, Närhi M, Lipponen JA, et al. Nitroglycerin-induced changes in facial skin
22 temperature: ‘cold nose’ as a predictor of headache? *Clin Physiol Funct Imaging* 2013;
23 n/a-n/a.
- 24 11. Headache Classification Committee of the International Headache Society (IHS). The
25 International Classification of Headache Disorders, 3rd edition (beta version).
26 *Cephalalgia Int J Headache* 2013; 33: 629–808.
- 27 12. American Academy of Thermology. Guidelines for neuro-musculoskeletal infrared
28 medical thermography and sympathetic skin response (SSR) studies,
29 [https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-](https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-musculoskeletal-thermography/)
30 [musculoskeletal-thermography/](https://aathermology.org/organization-2/guidelines/guidelines-for-neuro-musculoskeletal-thermography/) (accessed 12 June 2018).
- 31 13. Schwartz RG, Getson P, O’Young B, et al. Guidelines for Dental-Oral and Systemic
32 Health Infrared Thermography. *Pan Am J Med Thermol* 2015; 2: 44–53.
- 33 14. Fleiss JL. *The Design and Analysis of Clinical Experiments: Fleiss/The Design*.
34 Hoboken, NJ, USA: John Wiley & Sons, Inc. Epub ahead of print 8 February 1999.
35 DOI: 10.1002/9781118032923.
- 36 15. Lexell JE, Downham DY. How to assess the reliability of measurements in
37 rehabilitation. *Am J Phys Med Rehabil* 2005; 84: 719–723.

- 1
2
3 1 16. Antonaci F, Sand T, Lucas GA. Pressure algometry in healthy subjects: inter-examiner
4 2 variability. *Scand J Rehabil Med* 1998; 30: 3–8.
- 5
6 3 17. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol*
7 4 *Bull* 1979; 86: 420–428.
- 8
9 5 18. Ford R, Ford K. Thermography in the Diagnosis of Headache. *Semin Neurol* 1997; 17:
10 6 343–349.
- 11
12 7 19. Kurth F, Gaser C, Luders E. A 12-step user guide for analyzing voxel-wise gray matter
13 8 asymmetries in statistical parametric mapping (SPM). *Nat Protoc* 2015; 10: 293–304.
- 14
15 9 20. Anzola GP, Dalla Volta G, Di Monda V, et al. Laterality Indexes In Primary Headache :
16 10 Teletermography, Visual Evoked Potentials, Reaction Times. *Cephalalgia* 1987; 7: 301–
17 11 301.
- 18
19 12 21. Kudrow L. Thermographic and Doppler Flow Asymmetry in Cluster Headache.
20 13 *Headache J Head Face Pain* 1979; 19: 204–208.
- 21
22 14 22. Gawel M, Connolly JF, Rose FC. Migraine Patients Exhibit Abnormalities in the Visual
23 15 Evoked Potential. *Headache J Head Face Pain* 1983; 23: 49–52.
- 24
25 16 23. Raudino F. Visual evoked potential in patients with migraine. *Headache* 1988; 28: 531–
26 17 533.
- 27
28 18 24. Boylu E, Domaç FM, Koçer A, et al. Visual evoked potential abnormalities in migraine
29 19 patients. *Electromyogr Clin Neurophysiol* 2010; 50: 303–308.
- 30
31 20 25. Drummond PD. Vascular Changes in Atypical Facial Pain. *Headache J Head Face Pain*
32 21 1988; 28: 121–123.
- 33
34 22 26. Voiticovschi-Iosob C, Allena M, De Cillis I, et al. Diagnostic and therapeutic errors in
35 23 cluster headache: a hospital-based study. *J Headache Pain* 2014; 15: 56.
- 36
37
38 24 27. Antal A, Kriener N, Lang N, et al. Cathodal transcranial direct current stimulation of the
39 25 visual cortex in the prophylactic treatment of migraine. *Cephalalgia Int J Headache*
40 26 2011; 31: 820–828.
- 41
42 27 28. Dasilva AF, Mendonca ME, Zaghi S, et al. tDCS-induced analgesia and electrical fields
43 28 in pain-related neural networks in chronic migraine. *Headache* 2012; 52: 1283–1295.
- 44
45 29 29. DaSilva AF, Truong DQ, DosSantos MF, et al. State-of-art neuroanatomical target
46 30 analysis of high-definition and conventional tDCS montages used for migraine and pain
47 31 control. *Front Neuroanat* 2015; 9: 89.
- 48
49 32 30. Magis D. Neuromodulation in migraine: state of the art and perspectives. *Expert Rev*
50 33 *Med Devices* 2015; 12: 329–339.
- 51
52 34 31. Viganò A, D’Elia TS, Sava SL, et al. Transcranial Direct Current Stimulation (tDCS) of
53 35 the visual cortex: a proof-of-concept study based on interictal electrophysiological
54 36 abnormalities in migraine. *J Headache Pain* 2013; 14: 23.

- 1
2
3 1 32. Dmochowski JP, Datta A, Bikson M, et al. Optimized multi-electrode stimulation
4 2 increases focality and intensity at target. *J Neural Eng* 2011; 8: 046011.

5
6 3 **Figures legends**

7
8 4 **Figure 1-** Measurement point identification in patients. The radius of the circle was calculated
9
10 5 as the distance between the Nasion and the coolest point in the cold patch. Once defined the
11
12 6 radius, the second point was the point equidistant from the Nasion and with the same vertical
13
14 7 coordinate of the first point of measurement (symmetric point).
15

16 8
17
18 9 **Figure 2-** Measurement point identification in controls. The radius of the circle was constant.
19

20
21 10
22
23 11 **Figure 3 –** Mean FIT measured over 20 controls (left side) and 15 patients (right side) in
24
25 12 three consecutive readings (m1, m2, m3 - x axis) with 10 minutes of rest between readings
26
27 13 during T1 and T2. Error bars represent standard errors.
28

29 14
30
31 15 **Figure 4 -** Difference between left and right side as a percentage of the average temperature
32
33 16 in forehead (SideDifference) in patients (N=20) and controls (N=15).
34
35

36 17
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

297x190mm (72 x 72 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

213x190mm (72 x 72 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

360x141mm (72 x 72 DPI)

Peer Review




Figure 4

215x98mm (72 x 72 DPI)

STROBE Statement—checklist of items that should be included in reports of observational/case controlled studies, etc. **YOU MUST NOTE THE PAGE NUMBER WHERE EACH ITEM IS REPORTED INSIDE BRACKETS [] FOR EACH ITEM #. IF NOT APPLICABLE WRITE N/A**

	Item #	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	[3]	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2 [4]	Explain the scientific background and rationale for the investigation being reported
Objectives	3 [5/6]	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4 [7]	Present key elements of study design early in the paper
Setting	5 [6]	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6 [6]	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7 [7-9]	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8* [7-9]	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9 [n/a]	Describe any efforts to address potential sources of bias
Study size	10 [n/a]	Explain how the study size was arrived at
Quantitative variables	11 [7-9]	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12 [7-9]	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was

1
2 addressed

3 *Cross-sectional study*—If applicable, describe analytical methods taking account of
4 sampling strategy

5 (e) Describe any sensitivity analyses

6 Continued on next page
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13* [n/a]	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14* [6]	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15* [n/a]	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16 [n/a]	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17 [10-12]	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18 [12]	Summarise key results with reference to study objectives
Limitations	19 [13]	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20 [12-13]	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21 [13-14]	Discuss the generalisability (external validity) of the study results

Other information

Funding	22 [15]	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	------------	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.